Abelman RO et al. Sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): Multi-institution experience and biomarker analysis. San Antonio Breast Cancer Symposium 2023;Abstract PS08-03.

Bergeron A. et al. A clinicopathological study of HER2 status changes between primary breast cancer and subsequent metastasis in the new context of HER2-low therapy: Are there clinical or pathological characteristics that may predict evolution of HER2 status? Br J Cancer 2023;129(1):122-34. Abstract

Fernandez A. et al. Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol 2022;8(4):607-10. Abstract

Huppert L et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium 2023;Abstract PS08-04.

Lloyd MR et al. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Ther Adv Med Oncol 2022;14:1-25. Abstract

Tarantino P et al. Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer 2022;163:35-43. Abstract

Wolff AC. Highlights of the day I: Breast cancer – metastatic. ASCO 2024;Education Session. Abstract